Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HuA21 plus trastuzumab and chemotherapy in HER2-positive advanced or metastatic gastric cancer
CTR20240640Phase 2Active
- Sponsor
- Hefei HankeMab Biotechnology
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HuA21 in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Hefei HankeMab Biotechnology. Started Mar 2024; status: active.
02
Drugs
HuA21
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20240640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240640.